TO PUSH BACK ON PROGRESSION
33% reduction in the risk of death1
(ERLEADA® + ADT vs placebo + ADT; median overall survival was not estimable in either arm; HR=0.67; 95% CI: 0.51, 0.89; P=0.0053)
Review the results of the TITAN study published in The New England Journal of Medicine.
2-YEAR improvement in median MFS1
(ERLEADA® + ADT vs placebo + ADT; 40.5 months vs 16.2 months; HR=0.28; 95% CI: 0.23, 0.35; P<0.0001)
Review the results of the SPARTAN study published in The New England Journal of Medicine.
Final analysis publication
Review the final overall survival results of the SPARTAN study published in European Urology.
Patient-reported outcomes publication
Review patient-reported outcomes in the SPARTAN study published in The Lancet Oncology.
The articles above may only be available to subscribers of the respective journals. To access this content, you may have to sign in using your personal or institutional credentials. If you are not registered or a member of these journals, then you may need to purchase the articles through their sites.
Your One Source for Access, Affordability, and Treatment Support for Your Patients
Call a Janssen CarePath Coordinator at 877-CarePath (877-227-3728), Monday-Friday, 8:00 AM to 8:00 PM ET.
Sign Up or Log In to the Provider Portal at JanssenCarePathPortal.com.
Download a list of specialty pharmacies that distribute ERLEADA®.
*All patients who enrolled in the TITAN study started ADT for mCSPC ≤6 months prior to randomization.2
†In the SPARTAN study, conventional imaging (technetium-99m bone scans and CT scans) was used to confirm that patients were non-metastatic at screening for inclusion. Patients with pelvic lymph nodes <2 cm in short axis (N1) located below the iliac bifurcation at screening were allowed in the study. All patients in SPARTAN had a PSA doubling time ≤10 months at study entry.1,3
ADT = androgen deprivation therapy; CI = confidence interval; CT = computed tomography; HR = hazard ratio; mCSPC = metastatic castration-sensitive prostate cancer; MFS = metastasis-free survival; nmCRPC = non-metastatic castration-resistant prostate cancer; PSA = prostate-specific antigen; SPARTAN = Selective Prostate Androgen Receptor Targeting with ARN-509; TITAN = Targeted Investigational Treatment Analysis of Novel Antiandrogen.
1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
2. Chi KN, Agarwal N, Bjartell A, et al; for the TITAN Investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13-24.
3. Smith MR, Saad F, Chowdhury S, et al; for the SPARTAN Investigators. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408-1418.